Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies
We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples wit...
Gespeichert in:
| Veröffentlicht in: | Access microbiology 2021-08, Vol.3 (8), p.000257-000257 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 000257 |
|---|---|
| container_issue | 8 |
| container_start_page | 000257 |
| container_title | Access microbiology |
| container_volume | 3 |
| creator | Sekirov, Inna Petric, Martin Carruthers, Erin Lawrence, David Pidduck, Tamara Kustra, Jesse Laley, Jonathan Lee, Min-Kuang Chahil, Navdeep Mak, Annie Levett, Paul N. Mendoza, Emelissa Wood, Heidi Drebot, Mike Krajden, Mel Morshed, Muhammad |
| description | We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment. |
| doi_str_mv | 10.1099/acmi.0.000257 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8650845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2608536227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2097-dc52b1e93c917298461036955cd6e9fa27054f8f520dc4e3d7cea9c5d9dd1f243</originalsourceid><addsrcrecordid>eNpVkUFv1DAQhS0EolXpkbuPXLw4TpzYF6RqBaVSJRAtcLRm7clitLEXT1Jp-U38yCZsBe3J4zfP34z8GHtdyVUlrX0LfogruZJSKt09Y6dKV60wysrnj-oTdk70c_Eo21a1eslO6sYY0xh9yv58xtLnMkDyyH0e9lAi5cRzz4foSxYJp7HALv6GMc46EMGB-AYIA5_vNJWStzAiv7n4ciPW-ZtQHFLg328fK_HvSySKacvvYpnoP3iRPOzBx_GwzIU0RvGENsZNDhHpFXvRw47w_OE8Y18_vL9dfxTXny6v1hfXwitpOxG8VpsKbe1t1SlrmraSdWu19qFF24PqpG5602slg2-wDp1HsF4HG0LVq6Y-Y--O3P20GTB4TMumbl_iAOXgMkT3tJPiD7fNd860WppGz4A3D4CSf01IoxsiedztIGGeyKlWGl23SnWzVRyt82cTFez_jamkW0J2S8hOumPI9T2LSpvE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2608536227</pqid></control><display><type>article</type><title>Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Sekirov, Inna ; Petric, Martin ; Carruthers, Erin ; Lawrence, David ; Pidduck, Tamara ; Kustra, Jesse ; Laley, Jonathan ; Lee, Min-Kuang ; Chahil, Navdeep ; Mak, Annie ; Levett, Paul N. ; Mendoza, Emelissa ; Wood, Heidi ; Drebot, Mike ; Krajden, Mel ; Morshed, Muhammad</creator><creatorcontrib>Sekirov, Inna ; Petric, Martin ; Carruthers, Erin ; Lawrence, David ; Pidduck, Tamara ; Kustra, Jesse ; Laley, Jonathan ; Lee, Min-Kuang ; Chahil, Navdeep ; Mak, Annie ; Levett, Paul N. ; Mendoza, Emelissa ; Wood, Heidi ; Drebot, Mike ; Krajden, Mel ; Morshed, Muhammad</creatorcontrib><description>We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment.</description><identifier>ISSN: 2516-8290</identifier><identifier>EISSN: 2516-8290</identifier><identifier>DOI: 10.1099/acmi.0.000257</identifier><identifier>PMID: 34888485</identifier><language>eng</language><publisher>Microbiology Society</publisher><subject>Short Communications</subject><ispartof>Access microbiology, 2021-08, Vol.3 (8), p.000257-000257</ispartof><rights>2021 The Authors 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2097-dc52b1e93c917298461036955cd6e9fa27054f8f520dc4e3d7cea9c5d9dd1f243</citedby><cites>FETCH-LOGICAL-c2097-dc52b1e93c917298461036955cd6e9fa27054f8f520dc4e3d7cea9c5d9dd1f243</cites><orcidid>0000-0001-6854-1776 ; 0000-0002-3477-8748 ; 0000-0001-5042-7932</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650845/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650845/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,861,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Sekirov, Inna</creatorcontrib><creatorcontrib>Petric, Martin</creatorcontrib><creatorcontrib>Carruthers, Erin</creatorcontrib><creatorcontrib>Lawrence, David</creatorcontrib><creatorcontrib>Pidduck, Tamara</creatorcontrib><creatorcontrib>Kustra, Jesse</creatorcontrib><creatorcontrib>Laley, Jonathan</creatorcontrib><creatorcontrib>Lee, Min-Kuang</creatorcontrib><creatorcontrib>Chahil, Navdeep</creatorcontrib><creatorcontrib>Mak, Annie</creatorcontrib><creatorcontrib>Levett, Paul N.</creatorcontrib><creatorcontrib>Mendoza, Emelissa</creatorcontrib><creatorcontrib>Wood, Heidi</creatorcontrib><creatorcontrib>Drebot, Mike</creatorcontrib><creatorcontrib>Krajden, Mel</creatorcontrib><creatorcontrib>Morshed, Muhammad</creatorcontrib><title>Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies</title><title>Access microbiology</title><description>We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment.</description><subject>Short Communications</subject><issn>2516-8290</issn><issn>2516-8290</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkUFv1DAQhS0EolXpkbuPXLw4TpzYF6RqBaVSJRAtcLRm7clitLEXT1Jp-U38yCZsBe3J4zfP34z8GHtdyVUlrX0LfogruZJSKt09Y6dKV60wysrnj-oTdk70c_Eo21a1eslO6sYY0xh9yv58xtLnMkDyyH0e9lAi5cRzz4foSxYJp7HALv6GMc46EMGB-AYIA5_vNJWStzAiv7n4ciPW-ZtQHFLg328fK_HvSySKacvvYpnoP3iRPOzBx_GwzIU0RvGENsZNDhHpFXvRw47w_OE8Y18_vL9dfxTXny6v1hfXwitpOxG8VpsKbe1t1SlrmraSdWu19qFF24PqpG5602slg2-wDp1HsF4HG0LVq6Y-Y--O3P20GTB4TMumbl_iAOXgMkT3tJPiD7fNd860WppGz4A3D4CSf01IoxsiedztIGGeyKlWGl23SnWzVRyt82cTFez_jamkW0J2S8hOumPI9T2LSpvE</recordid><startdate>20210826</startdate><enddate>20210826</enddate><creator>Sekirov, Inna</creator><creator>Petric, Martin</creator><creator>Carruthers, Erin</creator><creator>Lawrence, David</creator><creator>Pidduck, Tamara</creator><creator>Kustra, Jesse</creator><creator>Laley, Jonathan</creator><creator>Lee, Min-Kuang</creator><creator>Chahil, Navdeep</creator><creator>Mak, Annie</creator><creator>Levett, Paul N.</creator><creator>Mendoza, Emelissa</creator><creator>Wood, Heidi</creator><creator>Drebot, Mike</creator><creator>Krajden, Mel</creator><creator>Morshed, Muhammad</creator><general>Microbiology Society</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6854-1776</orcidid><orcidid>https://orcid.org/0000-0002-3477-8748</orcidid><orcidid>https://orcid.org/0000-0001-5042-7932</orcidid></search><sort><creationdate>20210826</creationdate><title>Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies</title><author>Sekirov, Inna ; Petric, Martin ; Carruthers, Erin ; Lawrence, David ; Pidduck, Tamara ; Kustra, Jesse ; Laley, Jonathan ; Lee, Min-Kuang ; Chahil, Navdeep ; Mak, Annie ; Levett, Paul N. ; Mendoza, Emelissa ; Wood, Heidi ; Drebot, Mike ; Krajden, Mel ; Morshed, Muhammad</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2097-dc52b1e93c917298461036955cd6e9fa27054f8f520dc4e3d7cea9c5d9dd1f243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Short Communications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sekirov, Inna</creatorcontrib><creatorcontrib>Petric, Martin</creatorcontrib><creatorcontrib>Carruthers, Erin</creatorcontrib><creatorcontrib>Lawrence, David</creatorcontrib><creatorcontrib>Pidduck, Tamara</creatorcontrib><creatorcontrib>Kustra, Jesse</creatorcontrib><creatorcontrib>Laley, Jonathan</creatorcontrib><creatorcontrib>Lee, Min-Kuang</creatorcontrib><creatorcontrib>Chahil, Navdeep</creatorcontrib><creatorcontrib>Mak, Annie</creatorcontrib><creatorcontrib>Levett, Paul N.</creatorcontrib><creatorcontrib>Mendoza, Emelissa</creatorcontrib><creatorcontrib>Wood, Heidi</creatorcontrib><creatorcontrib>Drebot, Mike</creatorcontrib><creatorcontrib>Krajden, Mel</creatorcontrib><creatorcontrib>Morshed, Muhammad</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Access microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sekirov, Inna</au><au>Petric, Martin</au><au>Carruthers, Erin</au><au>Lawrence, David</au><au>Pidduck, Tamara</au><au>Kustra, Jesse</au><au>Laley, Jonathan</au><au>Lee, Min-Kuang</au><au>Chahil, Navdeep</au><au>Mak, Annie</au><au>Levett, Paul N.</au><au>Mendoza, Emelissa</au><au>Wood, Heidi</au><au>Drebot, Mike</au><au>Krajden, Mel</au><au>Morshed, Muhammad</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies</atitle><jtitle>Access microbiology</jtitle><date>2021-08-26</date><risdate>2021</risdate><volume>3</volume><issue>8</issue><spage>000257</spage><epage>000257</epage><pages>000257-000257</pages><issn>2516-8290</issn><eissn>2516-8290</eissn><abstract>We compared neutralization assays using either the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus or surrogate neutralization markers, using characterized sera. We found the results of the neutralization assays 75 % concordant overall and 80 % concordant for samples with high antibody levels. This demonstrates that commercial surrogate SARS-CoV-2 assays offer the potential to assess anti-SARS-CoV-2 antibodies’ neutralizing capacity outside CL-3 laboratory containment.</abstract><pub>Microbiology Society</pub><pmid>34888485</pmid><doi>10.1099/acmi.0.000257</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-6854-1776</orcidid><orcidid>https://orcid.org/0000-0002-3477-8748</orcidid><orcidid>https://orcid.org/0000-0001-5042-7932</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2516-8290 |
| ispartof | Access microbiology, 2021-08, Vol.3 (8), p.000257-000257 |
| issn | 2516-8290 2516-8290 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8650845 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Short Communications |
| title | Performance comparison of micro-neutralization assays based on surrogate SARS-CoV-2 and WT SARS-CoV-2 in assessing virus-neutralizing capacity of anti-SARS-CoV-2 antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T23%3A23%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Performance%20comparison%20of%20micro-neutralization%20assays%20based%20on%20surrogate%20SARS-CoV-2%20and%20WT%20SARS-CoV-2%20in%20assessing%20virus-neutralizing%20capacity%20of%20anti-SARS-CoV-2%20antibodies&rft.jtitle=Access%20microbiology&rft.au=Sekirov,%20Inna&rft.date=2021-08-26&rft.volume=3&rft.issue=8&rft.spage=000257&rft.epage=000257&rft.pages=000257-000257&rft.issn=2516-8290&rft.eissn=2516-8290&rft_id=info:doi/10.1099/acmi.0.000257&rft_dat=%3Cproquest_pubme%3E2608536227%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2608536227&rft_id=info:pmid/34888485&rfr_iscdi=true |